Hypothesis

Sustained ASK1‑MKK7‑JNK signaling, driven by mitochondrial ROS that persists beyond the first hour of stress, rewires AP‑1 dimer composition toward JunD/FosL1 heterodimers, which then preferentially bind and sustain transcription of a core SASP subset (IL‑6, IL‑8, MMP‑3) in senescent cells.

Mechanistic Rationale

1. Kinetic switch – Rapid JNK activation via GCKR/TRAF2 phosphorylates c‑Jun (Ser63/73) favoring c‑Jun/c‑Fos dimers that drive immediate‑early genes.
2. ROS‑dependent ASK1 – Mitochondrial ROS that accumulates over 20 min–1 h sustains ASK1 activity, leading to prolonged MKK7‑JNK signaling.
3. Dimer bias – Chronic JNK activity favors phosphorylation of JunD and FosL1 (which have lower turnover and distinct docking sites) over c‑Jun, shifting AP‑1 heterogeneity.
4. SASP lock‑in – JunD/FosL1‑AP‑1 binds composite sites with NF‑κB and C/EBPβ at SASP promoters, creating a feed‑forward loop that maintains SASP despite attenuation of upstream stress signals.
5. Mitochondrial dependence – Eliminating mitochondria (e.g., via Parkin overexpression) or scavenging ROS with MitoQ should prevent the JunD/FosL1 shift and attenuate SASP, even if acute JNK spikes occur.

Testable Predictions

• Prediction 1: In cells undergoing senescence (e.g., IR‑induced or oncogenic RAS), phospho‑JNK levels will show a biphasic pattern: an early peak (<15 min) followed by a sustained plateau (>2 h) that correlates with mitochondrial ROS measured by MitoSOX.
• Prediction 2: ChIP‑seq for JunD and FosL1 will reveal enriched binding at SASP gene promoters (IL6, CXCL8, MMP3) only after the sustained JNK phase, whereas c‑Jun/c‑Fos binding will be transient and lost after 6 h.
• Prediction 3: Genetic ablation of ASK1 or pharmacological inhibition (e.g., GS‑444217) will block the sustained JNK phase, prevent JunD/FosL1 dimer accumulation, and reduce SASP secretion without affecting the early c‑Jun‑c‑Fos response.
• Prediction 4: Forced expression of a phospho‑mimetic JunD (Ser‑→‑Asp) will rescue SASP expression in ASK1‑deficient senescent cells, indicating that JunD activation is downstream of sustained JNK.

Experimental Approach

• Use human diploid fibroblasts (IMR‑90) and induce senescence via 10 Gy ionizing radiation or inducible HRAS^G12V.
• Measure mitochondrial ROS (MitoSOX), phospho‑JNK (Thr183/Tyr185) by western blot and live‑cell FRET biosensor at 0, 0.5, 2, 6, 24 h.
• Perform co‑immunoprecipitation followed by mass spectrometry to quantify AP‑1 dimer isoforms across time points.
• Conduct ChIP‑seq for JunD, FosL1, c‑Jun, c‑Fra‑1 at 2 h and 24 h.
• Apply ASK1 KO (CRISPR) or GSK‑690693, MKK7 siRNA, and MitoQ treatment; assess SASP cytokine secretion by ELISA and p16^INK4a/p21^CIP1 expression.
• Rescue experiments with JunD‑S/D phospho‑mimetic plasmid.

Potential Outcomes and Falsifiability

• If sustained JNK, JunD/FosL1 enrichment, and SASP maintenance are all abolished by ASK1 inhibition or MitoQ while early JNK/c‑Jun activity remains, the hypothesis is supported.
• If JunD/FosL1 binding does not increase despite prolonged JNK activity, or SASP persists despite loss of JunD/FosL1, the hypothesis is falsified, indicating that alternative AP‑1 complexes or JNK‑independent pathways drive SASP lock‑in.